Vnitr Lek 2009, 55(4):425-428

Insulin Sensitizing Drugs

A. ©mahelová
Diabetologické centrum, vedoucí doc. MUDr. Alena ©mahelová, Ph.D., Kliniky gerontologické a metabolické Lékařské fakulty UK a FN Hradec Králové, přednosta prof. MUDr. Luboą Sobotka, CSc.

Currently, insulin sensitizing drugs in the form of metformin as the basic drug are part of the treatment of practically any type II diabetic patient. At the beginning of the therapy, metformin is used; later, insulin sensitizers (PPAR-γ stimulators) such as rosiglitazone and pioglitazone are often applied. Nowadays, extensive research into new pharmaceuticals is being conducted in the group of insulin sensitizers. So-called double sensitizers, panPPAR sensitizers or PPAR-δ sensitizers, are being developed. The most promising group is of the PPAR-γ selective modulators.

Keywords: metformin; rosiglitazone; pioglitazone; PPAR sensitizers; selective PPAR modulators; panPPAR sensitizers

Received: February 14, 2009; Published: April 1, 2009  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
©mahelová A. Insulin Sensitizing Drugs. Vnitr Lek. 2009;55(4):425-428.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Zwieten PA, Lancia G. The metabolic syndrome - a therapeutic chalenge. European society of hypertension 2005.
    2. Nathan DM, Buse JB, Davidson MB et al. American Diabetes Association; European Association for Study of Diabetes. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009; 32: 193-203. Go to original source... Go to PubMed...
    3. Rosenstock J. Reflecting on type 2 diabetes prevention: more questions than answers. Diabetes Obes Metab 2007; 9 (Suppl 1): 3-11. Go to original source... Go to PubMed...
    4. ©mahelová A. Metformin. In: Haluzík M (ed). Trendy v endokrinologii č. 12. Praha: Galén 2008.
    5. DPP Research group: The Diabetes Prevention Program (DPP): description of lifestyle intervention. Diabetes Care 2002; 25: 2165-2171. Go to original source... Go to PubMed...
    6. Haluzík M, Svačina ©. Metabolický syndrom a jaderné receptory PPAR. Praha: Grada Publishing 2005.
    7. Cavaghan MK, Ehrmann DA, Byrne MM et al. Treatment with the oral antidiabetic agent troglitazone improves beta cell responses to glucose in subjects with impaired glucose tolerance. J Clin Invest 1997; 100: 530-537. Go to original source... Go to PubMed...
    8. Kahn SE, Haffner SM, Heise MA et al. ADOPT Study Group. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006; 355: 2427-2443. Go to original source... Go to PubMed...
    9. Yki-Järvinen H. Thiazolidinediones. N Engl J Med 2004; 351: 1106-1118. Go to original source... Go to PubMed...
    10. Goldberg RB, Kendall DM, Deeg MA et al. GLAI Study Investigators. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care 2005; 28: 1547-1554. Go to original source... Go to PubMed...
    11. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007; 356: 2457-2471. Go to original source... Go to PubMed...
    12. Dormandy JA, Charbonnel B, Eckland DJ et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005; 366: 1279-1289. Go to original source... Go to PubMed...
    13. Home PD, Jones NP, Pocock SJ et al. RECORD Study Group. Rosiglitazone RECORD study: glucose control outcomes at 18 months. Diabet Med 2007; 24: 626-634. Go to original source... Go to PubMed...
    14. Loke YK, Singh S, Furberg CD. Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis. CMAJ 2009; 180: 32-39. Go to original source... Go to PubMed...
    15. Svačina ©. Prevence diabetu a jeho komplikací. Praha: Triton 2008.
    16. Gross B, Staels B. PPAR agonists: multimodal drugs for the treatment of type-2 diabetes. Best Pract Res Clin Endocrinol Metab 2007; 21: 687-710. Go to original source... Go to PubMed...
    17. Svačina ©. Metabolické receptory PPAR a kůľe. Vnitř Lék 2006; 52: 451-453. Go to PubMed...
    18. Tenenbaum A, Motro M, Fisman EZ. Dual and pan-peroxisome proliferator-activated receptors (PPAR) co-agonism: the bezafibrate lessons. Cardiovasc Diabetol 2005; 4: 14. Go to original source... Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.